Oncogenic protein interfaces: small molecules, big challenges
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein–protein interactions (PPIs) play a crucial role in numerous biological processes, including signal transduction, cell proliferation, growth, differentiation, apoptosis.303–305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“However, their suitability for tight and narrow PPI interfaces and poor selectivity limits their application in targeting PPIs.305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“PPIs have relatively large and amorphous interfaces, rather than small and well-defined crevices.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
In the citing paper
“Compared with targeting enzymes or receptors, however, the development of molecules targeting PPIs has been challenging [22–24].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 1
- Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1–9 (2011).
Cited by
Items 201–300 of 319
Unraveling the role of physicochemical differences in predicting protein–protein interactions
Teimouri, H., Medvedeva, A., & Kolomeisky, A. B. (2024) · The Journal of Chemical Physics · doi:10.1063/5.0219501 · Cited by 10
Chou, Y., Hsu, F., Hu, D.-Y., Chen, Y., Hsu, Y., Hsu, J. T.-A., & Chau, L. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0411-y · Cited by 12
Ria, F., Pirolli, D., Sante, G. D., Righino, B., Gremese, E., Gervasoni, J., Nicolò, C., Giardina, B., Ferraccioli, G., & Rosa, M. C. D. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00601 · Cited by 9
Martin, L. L., Rodgers, R. J., Corbin, C. J., Conley, A. J., Parker, M. W., & Holien, J. K. (2017) · Current Protein and Peptide Science · doi:10.2174/1389203717666161220142957 · Cited by 9
Self-citationIannello, A., Ciarrocchi, A., Fragliasso, V., & Vaisitti, T. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215645 · Cited by 8
Lanjanian, H., Hosseini, S., Narimani, Z., Meknatkhah, S., & Riazi, G. H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2163425 · Cited by 8
“Therefore, it seems that the small molecule-based drug design is not suitable enough to inhibit PPI interfaces (Nero et al., 2014).”
BackgroundYeom, E., Kwon, D.-W., Lee, J., Kim, S., Lee, J.-H., Min, K., Lee, K., & Yu, K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00032 · Cited by 9
Iqbal, M. S., Siddiqui, A. A., Banerjee, C., Nag, S., Mazumder, S., De, R., Saha, S. J., Karri, S. K., & Bandyopadhyay, U. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.04.005 · Cited by 11
Ribeiro, H. D. O., Cortez, A. P., de Ávila, R. I., da Silva, A. C. G., de Carvalho, F. S., Menegatti, R., Lião, L. M., & Valadares, M. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12540 · Cited by 8
Rubin, S. J. S., & Qvit, N. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201021141401 · Cited by 9
Bryant, P., & Noé, F. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.15.536993 · Cited by 9
“Protein-protein interactions (PPIs) govern many cellular processes [1,2] and are essential for understanding and identifying disease targets [3].”
BackgroundWiedmann, M. M., Tan, Y. S., Wu, Y., Aibara, S., Xu, W., Sore, H. F., Verma, C. S., Itzhaki, L. S., Stewart, M., Brenton, J. D., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201609427 · Cited by 7
Póti, Á., Dénes, L., Papp, K., Bató, C., Bánóczi, Z., Reményi, A., & Alexa, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914854 · Cited by 7
“However, protein–protein binding surfaces are generally shallow compared to the deep ATP-binding pocket which could hamper the identification of good binders [20,21].”
BackgroundCurrent Computational Methods for Protein-peptide Complex Structure Prediction
Yang, C., Xu, X., & Xiang, C. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673263447230920151524 · Cited by 7
Yu, B., & Liu, H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_8 · Cited by 11
Lubell, W. D. (2016) · Topics in heterocyclic chemistry · doi:10.1007/978-3-319-49124-0 · Cited by 7
Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
Massudi, H., Luo, J.-S., Holien, J. K., Gadde, S., Krishan, S., Herath, M., Koach, J., Stevenson, B. W., Gorman, M. A., Venkat, P., et al. (2023) · Cancers · doi:10.3390/cancers15061822 · Cited by 7
“Small molecule inhibition of protein-protein interfaces is a challenge due to the undruggable nature of a protein-protein interface [13].”
BackgroundSelf-citationIn‐Bridge Stereochemistry: A Determinant of Stapled Peptide Conformation and Activity
Zhang, J., & Dong, S. (2024) · ChemBioChem · doi:10.1002/cbic.202300747 · Cited by 6
Sarkar, D., Patra, P., Ghosh, A., & Saha, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155911 · Cited by 7
“Recent studies have shown that small chemical inhibitors can target PPIs, including the ones mediated by short peptides, and have the potential to act as new therapeutic agents against complex diseases including cancer [13].”
BackgroundMatossian, M. D., Elliott, S. G., Hoang, V. T., Burks, H. E., Phamduy, T. B., Chrisey, D. B., Zuercher, W. J., Drewry, D. H., Wells, C. I., Collins‐Burow, B. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177802 · Cited by 6
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development
Vo, D.-K., & Trinh, K. T. L. (2025) · Micromachines · doi:10.3390/mi16030243 · Cited by 9
“Well-known high-throughput screening (HTS) technologies make use of new biomarker identi fi cations [72,73]. for identification and screening [74,75].”
Exploring computational tools for improved structural design and stability of helical AApeptides
Li, T., Song, S., & He, Y. J. (2023) · Supramolecular Materials · doi:10.1016/j.supmat.2023.100038 · Cited by 5
PPI-hotspotID for detecting protein–protein interaction hot spots from the free protein structure
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · eLife · doi:10.7554/elife.96643 · Cited by 11
“Protein–protein interactions (PPIs) play a crucial role in cellular physiology, and their dysregulation is associated with various diseases ( David et al., 2012 ) such as cancer ( Nero et al., 2014 ), infectious diseases, and neurodegenerative diseases ( Blazer and Neubig, 2009 ).”
Bogdańska-Chomczyk, E., Rowniak, M., Wojtacha, P., Tsai, M. L., Huang, A. C. W., & Kozłowska, A. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1414457 · Cited by 5
Yoou, M., Cho, S., & Choi, Y. (2019) · BioChip Journal · doi:10.1007/s13206-019-3306-4 · Cited by 6
Kim, D. G., Huddar, S., Lim, S., Kong, J., Lee, Y., Park, C. M., Lee, S., Suh, Y., Kim, M., Lee, K., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000766 · Cited by 6
“This work provides an example showing that allosteric conformational changes induced by chemicals can be a way to control pathologic PPIs.”
BackgroundInfluentialThe lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma
Ferreira, G. A., Thomé, C. H., Simão, A. M., Scheucher, P. S., Silva, C. L. A., Chahud, F., Ciancaglini, P., Leopoldino, A. M., Rego, E. M., Faça, V. M., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1607326 · Cited by 5
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis
Cheung, B. B., Mittra, R., Murray, J. E., Wang, Q., Seneviratne, J. A., Raipuria, M., Wong, I. P. L., Restuccia, D. F., Gifford, A. J., Salib, A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06899-8 · Cited by 5
“Multiple recent successes in the design of protein-protein interface inhibitors for clinical use indicate this is a feasible strategy for blocking RNF121-MYCN binding 49 .”
Self-citationSmall Molecules Targeting the Transmembrane Domain
Wang, Y., & Wang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01876 · Cited by 4
Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein‐Protein Interaction
Oberman, R., Yemane, B., Jarvis, C. M., Franco, F. M., Kyriukha, Y. A., Nolan, W. C., Gohara, B., Krezel, A. M., Wildman, S. A., & Janetka, J. W. (2024) · ChemMedChem · doi:10.1002/cmdc.202300648 · Cited by 6
Chen, S., Li, M., Xue, C., Zhou, X., Wei, J., Zheng, L., Duan, Y., Deng, H., Tang, F., Xiong, W., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s443305 · Cited by 4
“42,43 Therefore, we only representatively selected the protein molecules (CDK1, CDK4, PLK1, CHEK1, and TTK) that have been reported to have inhibitors for further molecule docking, and all these proteins belong to kinases, which have ATP active sites and definite binding pockets, while most kinase…”
BackgroundLima, M. C. P., Hornsby, B. D., Lim, C. S., & Cheatham, T. E. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c02699 · Cited by 5
Lau, H. R., Smith, H. S., Alural, B., Martin, C. E., New, L. A., Tilak, M., Banerjee, S. L., Robeson, H. N., Bisson, N., Gingras, A., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70022 · Cited by 5
“Inter-estingly, the ShcD interactome aligns with tyrosine kinase inhibitor resistance, supporting an avenue to target protein – protein interactions rather than individual RTKs in these tumors [103 – 105].”
Prediction of transient and permanent protein interactions using AI methods
Rathore, R. S. (2023) · Bioinformation · doi:10.6026/97320630019749 · Cited by 5
Targeting Protein–Protein Interactions Perspective
Chung, C., & Hann, M. M. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch20 · Cited by 6
Wang, Y., & Wang, X. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2198699 · Cited by 4
“The PPI interface has been classified as ‘undruggable,’ because the PPI interface area usually tends to be large and flat with limited grooves or pockets, making it difficult for small molecules to bind [1,2].”
BackgroundKanakaveti, V., Anoosha, P., Sakthivel, R., Rayala, S. K., & Gromiha, M. M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304143354 · Cited by 3
Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation
Ibrahim, S., Khan, M. U., Noreen, S., Firdous, S., Khurram, I., Rehman, R., Javed, M. A., & Ali, Q. (2025) · Cytotechnology · doi:10.1007/s10616-025-00716-8 · Cited by 3
“They also provide light on an important molecular mechanism for these medications (Nero et al. 2014).”
Small-molecule Modulators of Protein–Protein Interactions: Focus on 14-3-3 PPIs
Iralde-Lorente, L., Botta, M., & Ottmann, C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00249 · Cited by 3
Application of Fragment‐Based Screening to the Design of Inhibitors of Escherichia coli DsbA
Adams, L. A., Sharma, P., Mohanty, B., Ilyichova, O. V., Mulcair, M. D., Williams, M. L., Gleeson, E. C., Totsika, M., Doak, B. C., Caria, S., et al. (2014) · Angewandte Chemie · doi:10.1002/ange.201410341 · Cited by 3
Wu, S., Xiao, M., Liu, F., Hong, H.-Y., Ding, C., Zhang, X., & Xie, W. (2024) · Discover Oncology · doi:10.1007/s12672-024-01661-2 · Cited by 4
“PPIs play a pivotal role in regulation of biological systems and are consequently involved in the progression of disease states [30].”
Nakadai, M., Tomida, S., & Sekimizu, K. (2016) · Scientific Reports · doi:10.1038/srep18543 · Cited by 3
Alphappimi: a comprehensive deep learning framework for predicting PPI-modulator interactions
Liu, D., Song, T., Wang, S., Li, X., Han, P., Wang, J., & Wang, S. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01077-2 · Cited by 2
“Unlike traditional drug targets, PPI targets typically lack well-defined binding pockets and are characterized by flat, hydrophobic interaction interfaces [9].”
Duan, T.-H., Jiang, X., Zhang, Z., Xu, R., Li, R., Wang, X., Niu, L., & Feng, W. S. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70188 · Cited by 2
Bokobza, C., Réda, C., Nair, S., Guenoun, D., Rocha‐Ferreira, E., Faivre, V., Charpentier, T. L., Nijboer, C. H. A., de Theije, C. G. M., Lebon, S., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03593-2 · Cited by 3
Drug leads for interactive protein targets with unknown structure
Fernández, A., & Scott, R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.006 · Cited by 2
Lee, J., Seok, C., Ham, S., & Chong, S. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26458 · Cited by 3
Drug Design Methods to Regulate Protein–Protein Interactions
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 4
Crystallography and New Medicines: Examples from Influenza and Cell Death
Colman, P. M. (2014) · Australian Journal of Chemistry · doi:10.1071/ch14318 · Cited by 2
Villoutreix, B. O. (2016) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2016.03.006 · Cited by 2
Awuni, E. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.814935 · Cited by 2
“, 2014), however, remarkable progress has been made in targeting PPIs and currently, there are approved PPI drugs with many other PPI inhibitors in clinical trials (Wells and Mcclendon, 2007; Nero et al., 2014; Scott et al., 2016; Lu et al., 2020).”
BackgroundThe rise of nanotoxicology: A successful collaboration between engineering and biology
Comfort, K. K. (2016) · AIMS bioengineering · doi:10.3934/bioeng.2016.3.230 · Cited by 2
Other Nonbiological Approaches to Targeted Cancer Chemotherapy
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00011-9 · Cited by 3
Multivalent Protein Recognition Using Synthetic Receptors
Gupta, A., Ray, M., & Rotello, V. M. (2017) · Wiley eBooks · doi:10.1002/9781119143505.ch10 · Cited by 2
Lü, L., Li, H., Su, T., & Ming, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179172 · Cited by 1
“The interactions of proteins with other molecules are the basis of many essential physiological processes, such as the cytoskeleton assembly, muscle energy supply, enzymatic reactions, cell signaling, etc. [1,2].”
BackgroundKulyyassov, A., Makhsatova, S., & Kurmanbay, A. (2025) · Applied Sciences · doi:10.3390/app15020666 · Cited by 2
The rise of NMR-integrated fragment-based drug discovery in China
Li, Z., Wang, L., Gao, J., & Ruan, K. (2025) · Magnetic Resonance Letters · doi:10.1016/j.mrl.2025.200179 · Cited by 2
“Protein-protein interactions network within cells [38] regulate intricate biological processes such as signaling, cell proliferation, and apoptosis [39,40].”
Khan, M. W. A., Alam, M. J., Sherwani, S., Alouffi, S., Al-Motair, K. A., Khan, S. A., & Khan, S. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010038 · Cited by 2
“Approximately 130,000–650,000 different types of PPIs exist in humans [8,9], playing a crucial role in physiological and pathological processes, including cell growth, differentiation, apoptosis, and signal transduction [8,9].”
SPOP and HAUSP bidirectionally regulate LZTS2 ubiquitination to modulate the Wnt pathway
Deng, Y., Xie, C., Liu, R., Ma, K., Tang, J. B., & Zhou, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08351-z · Cited by 1
“…as follows: MOCK -siRNA, 5 ’ -UUC UCC GAA CGU GUC ACG UUU dTdT-3 ’ , LZTS2 -siRNA1, 5 ’ -GGA GGA GAU CAC UGC UAC U dTdT-3 ’ , LZTS2 - siRNA2, 5 ’ -GCA GCA GCU GAA AGA GUC U dTdT-3 ′ , HAUSP -siRNA1, 5 ’ -ACC CUU GGA CAA UAU UCC U dTdT-3 ’ , HAUSP -siRNA2, 5 ′ -AGU CGU UCA GUC GUC GUA U dTdT-3 ’ .”
Inhibition of Wnt Signaling Using Axin Peptidomimetics through Direct Targeting of β-Catenin
Sang, P., Wei, J., Qian, Y., Wu, M., Song, T., Li, W., Wei, J., Li, B., Zhang, J., Cai, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00318 · Cited by 1
Interpretable deep learning framework for mapping E3–substrate binding interfaces
Li, D., Zhang, Y., Liu, Y., Zhang, Z., Qu, Y., Li, J., Jiang, L., Diao, L., Zhang, Z., Zhang, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73143-8 · Cited by 1
“We then integrated TCGA driver gene annotations from IntOGen and cancer driver genes from the Cancer Gene Census to identify E3s whose interface mutations confer cancer-driving effects (termed OncoE3; Supplementary Data 9).”
Oligooxopiperazines as Topographical Helix Mimetics
Lao, B. B., & Arora, P. S. (2016) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_195 · Cited by 1
Future of Medicinal Chemistry: Next-Generation Therapeutics
Tsomaia, N., Ufret, M. D. L., Bhat, A., & Nakhlé, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12294-2 · Cited by 2
Microscale measurements of protein complexes from single cells
Dutta, T., & Vlassakis, J. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102860 · Cited by 1
Ohkanda, J. (2017) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.75.735 · Cited by 1
Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
Dong, G., & Sheng, C. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_1 · Cited by 1
An Alternate View of Neuroprotection with Peptides in Alzheimer’s Disease
King, S. P., & Suphioglu, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91065 · Cited by 1
Beekman, A. M., O'Connell, M. A., & Howell, L. A. (2017) · Angewandte Chemie · doi:10.1002/ange.201705008 · Cited by 1
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3400169/v1 · Cited by 1
Teimouri, H., Medvedeva, A., & Kolomeisky, A. B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.27.582345 · Cited by 1
“Furthermore, protein-protein interactions are closely associated with the development and progress of various diseases, including viral pathogenesis [7], cancer [23], and neurodegenerative diseases [31,36].”
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · eLife · doi:10.7554/elife.96643.1 · Cited by 1
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · eLife · doi:10.7554/elife.96643.2 · Cited by 2
Inhibition of the MDM2/p53 Interaction Design, Synthesis and Evaluation of MDM2 Inhibitors
Pettersson, M. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
dos Santos, R. N. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2016.tde-02022016-163931 · Cited by 1
Fernández, A. (2016) · Soft and biological matter · doi:10.1007/978-3-319-30852-4_16
Protein-guided Self-Assembly for Controlling Protein–Protein Interactions
Ohkanda, J. (2017) · Journal of The Society of Japanese Women Scientists · doi:10.5939/sjws.17001
Fernández, A. (2015) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000e149
“When PPAs involve binding partners altered in a disease-related context, complex formation may lead to deregulation of biological function and a drug-based disruption of the complex represents a therapeutic opportunity [2-4].”
BackgroundTargeting the menin-MLL-LEDGF Interaction with Small Molecule Inhibitors.
Pollock, J. (2016) · Deep Blue (University of Michigan)
Agthoven, J. F. V., Shams, H., Cochran, F. V., Alonso, J. L., Kintzing, J. R., Garakani, K., Xiong, J.-P., Mofrad, M. R. K., Cochran, J. R., & Arnaout, M. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/565358
“development of multifunctional small molecule integrin antagonists that maintain high affinity and suitable pharmacokinetic properties remains a challenge (Nero et al., 2014).”
Bazzoli, A., & Contini, A. (2020) · Research Square · doi:10.21203/rs.3.rs-69979/v1
Recent Trend in Physical Sciences
(2021) · Lincoln Research and Publications Limited, Australia in Collaboration with Lincoln University College, Malaysia eBooks · doi:10.31674/book.2021.rtps
Hu, K. (2021) · Springer theses · doi:10.1007/978-981-33-6613-8_1
Copeland, R. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733651684.793549798
Engineering constrained peptides to target nucleic acids: G-quadruplex recognition and imaging
Yavorova, Y. M. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/157352
Interactions of Fibrillar Insulin with Proteins: A Molecular Docking Study
Trusova, V. M., Zhytniakivska, O. A., Tarabara, U. K., Vus, K. O., & Gorbenko, G. P. (2022) · East European Journal of Physics · doi:10.26565/2312-4334-2022-2-17
Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance
Nandi, S., Mondal, A., Ghosh, A., Mukherjee, S., & Das, C. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.002
General aspects of cancer therapy
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00002-9
Becht, A., Frączyk, J., Waśko, J., Menaszek, E., Kajdanek, J., Miłowska, K., & Kolesińska, B. (2023) · Journal of Peptide Science · doi:10.1002/psc.3537
Molecular characterization of FOX factors and Wnt signalling interplay in human cancers
Pizzolato, G. (2023) · Linköping University medical dissertations · doi:10.3384/9789180753364
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · Research Square · doi:10.21203/rs.3.rs-3400169/v2
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · Research Square · doi:10.21203/rs.3.rs-3400169/v3
Chen, Y. C., Sargsyan, K., Wright, J. D., et al. (2024) · eLife · doi:10.7554/elife.96643.2.sa1
Chen, Y. C., Sargsyan, K., Wright, J. D., Chen, Y., Huang, Y., & Lim, C. (2024) · eLife · doi:10.7554/elife.96643.2.sa0
Lü, X., Wang, C., Tang, M., Li, J., Xia, Z., Fan, S., Jin, Y., & Yang, Z. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108450 · Cited by 1
Application of Sulfonyl‐γ‐AApeptides for PPI Drug Discovery
Fontaine, J., & Cai, J. (2025) · doi:10.1002/9783527845828.ch9
Hashemi, M., Salimian, N., Sharifi, N., Asheghabadi, P. S., Zarearandi, Z., Abdi, F., Akbar, S. S., Shirazi, R. M., Pozve, M. B., Nikdehqan, A., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03999-1
“Advancements in oligonucleotide-based therapeutic strategies now enable targeting previously inaccessible human transcriptome components that resist conventional small molecule or antibody-based interventions [251, 252].”
Wei, Z., Wei, L., Hu, Y. A., Chen, P., Chen, Y., Wang, K., Weng, J., Xing, B., Ming, K., Wu, Z., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8525913/v1
Metadata
- Authors
- Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W.
- Affiliations
- Australian Cancer Research Foundation (AU)
- The University of Melbourne (AU)
- Corresponding author
- Parker, Michael W.
- Venue
- Nature Reviews Cancer
- Published
- 2014-03-13
- Volume
- 14
- Issue
- 4
- Pages
- 248-262
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2003516462
- Cited by
- 312
- References
- 161
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 35 · 2023: 29 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 19 · 2018: 26 · 2017: 24 · 2016: 34 · 2015: 37 · 2014: 15
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, oncoprotein, small molecule modulators, drug discovery, undruggable targets, protein-protein interaction surfaces, cancer drug targets
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Drug Screening Assays, Antitumor, Humans, Neoplasms, Protein Binding, Surface Properties, Oncogene Proteins, Protein Interaction Domains and Motifs, Protein Interaction Maps, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.